LUMOS PHARMA INC. - COMMON STOCK

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma

12 дек 2024 07:47:38 Источник Nasdaq GlobeNewswire

Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action

21 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire

Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024

30 окт 2024 15:05:00 Источник Nasdaq GlobeNewswire

Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)

23 окт 2024 07:00:01 Источник Nasdaq GlobeNewswire

Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024

25 сен 2024 15:05:00 Источник Nasdaq GlobeNewswire

Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024

05 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire

Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

15 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire

Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update

01 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire

Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024

23 июл 2024 15:05:00 Источник Nasdaq GlobeNewswire

Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024

04 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire

Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024

20 май 2024 15:05:00 Источник Nasdaq GlobeNewswire

Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results

14 май 2024 15:15:00 Источник Nasdaq GlobeNewswire

Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024

09 май 2024 13:51:02 Источник Nasdaq GlobeNewswire

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

18 апр 2024 15:05:00 Источник Nasdaq GlobeNewswire

Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042

20 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

07 мар 2024 15:01:00 Источник Nasdaq GlobeNewswire

Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

26 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference

05 фев 2024 15:05:01 Источник Nasdaq GlobeNewswire

Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

21 ноя 2023 15:15:00 Источник Nasdaq GlobeNewswire

Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November

20 ноя 2023 15:05:00 Источник Nasdaq GlobeNewswire